Effects of and Moluodan on the Wnt/β-catenin signaling pathway in mice with precancerous gastric cancer lesions.

Background: () is the primary risk factor for gastric cancer (GC), the Wnt/β-Catenin signaling pathway is closely linked to tumourigenesis. GC has a high mortality rate and treatment cost, and there are no drugs to prevent the progression of gastric precancerous lesions to GC. Therefore, it is necessary to find a novel drug that is inexpensive and preventive to against GC.

Aim: To explore the effects of and Moluodan on the Wnt/β-Catenin signaling pathway and precancerous lesions of GC (PLGC).

Methods: Mice were divided into the control, N-methyl-N-nitrosourea (MNU), + MNU, and Moluodan groups. We first created an infection model in the + MNU and Moluodan groups. A PLGC model was created in the remaining three groups except for the control group. Moluodan was fed to mice in the Moloudan group ad libitum. The general condition of mice were observed during the whole experiment period. Gastric tissues of mice were grossly and microscopically examined. Through quantitative real-time PCR (qRT-PCR) and Western blotting analysis, the expression of relevant genes were detected.

Results: Mice in the + MNU group showed the worst performance in general condition, gastric tissue visual and microscopic observation, followed by the MNU group, Moluodan group and the control group. QRT-PCR and Western blotting analysis were used to detect the expression of relevant genes, the results showed that the + MNU group had the highest expression, followed by the MNU group, Moluodan group and the control group.

Conclusion: can activate the Wnt/β-catenin signaling pathway, thereby facilitating the development and progression of PLGC. Moluodan suppressed the activation of the Wnt/β-catenin signaling pathway, thereby decreasing the progression of PLGC.